VEGFA and hepatocellular carcinoma: In line, portal vein tumour thrombosis is associated with an increased risk of high-risk varices and variceal bleeding in patients with HCC, particularly in individuals receiving vascular endothelial growth factor (VEGF)-targeted agents [13].